Fenwick Represents Maze Therapeutics in $190 Million Financing

By: Effie Toshav, Matthew Rossiter, Myles Gutenkunst, Peter Li

Fenwick represented Maze Therapeutics, a company translating genetic insights into new precision medicines, in its $190 million financing, led by from Matrix Capital Management with participation from General Catalyst, a16z Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and several others.

The financing will allow Maze to support advancement of the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need. More information can be obtained from Maze’s announcement.

The Fenwick transaction team included corporate partners Effie Toshav and Matthew Rossiter, and associates Eugene Karlik, Myles Gutenkunst and Peter Li.

Login

Don’t have an account yet?

Register